3 Stocks Estimated To Be Trading At Discounts Ranging From 31% To 42.6%

In This Article:

As global markets react to cautious Federal Reserve commentary and political uncertainties, investors are navigating a complex landscape marked by rate cuts and economic resilience. Amid these fluctuations, the search for undervalued stocks becomes increasingly relevant, as they can offer potential opportunities when broader market sentiment is uncertain. In this environment, identifying stocks trading at significant discounts may provide value-oriented investors with a chance to capitalize on mispriced assets.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Round One (TSE:4680)

¥1310.00

¥2607.13

49.8%

Xiamen Bank (SHSE:601187)

CN¥5.69

CN¥11.34

49.8%

Lindab International (OM:LIAB)

SEK226.40

SEK450.98

49.8%

Absolent Air Care Group (OM:ABSO)

SEK255.00

SEK509.76

50%

NCSOFT (KOSE:A036570)

₩205500.00

₩409953.04

49.9%

Pluk Phak Praw Rak Mae (SET:OKJ)

THB15.50

THB30.86

49.8%

STIF Société anonyme (ENXTPA:ALSTI)

€24.60

€49.15

49.9%

Informa (LSE:INF)

£7.992

£15.92

49.8%

Surgical Science Sweden (OM:SUS)

SEK159.10

SEK317.10

49.8%

Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707)

CN¥13.24

CN¥26.38

49.8%

Click here to see the full list of 870 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

Datalogic

Overview: Datalogic S.p.A. manufactures and sells automatic data capture and process automation products globally, with a market cap of €267.96 million.

Operations: Datalogic's revenue segments include automatic data capture and process automation products sold globally.

Estimated Discount To Fair Value: 31%

Datalogic is trading at €5, significantly below its fair value estimate of €7.24, indicating it may be undervalued based on cash flows. Despite a decline in sales to €366.36 million for the nine months ended September 2024, net income increased to €12.57 million from the previous year. Earnings are forecasted to grow significantly by 23.4% annually, outpacing both revenue growth and Italian market averages, though profit margins have decreased recently.

BIT:DAL Discounted Cash Flow as at Dec 2024
BIT:DAL Discounted Cash Flow as at Dec 2024

Takara Bio

Overview: Takara Bio Inc. operates in the bioindustry, CDMO, and gene therapy sectors across Japan, China, the rest of Asia, the United States, Europe, and internationally with a market cap of ¥120.78 billion.

Operations: The company generates revenue from its Drug Discovery segment, amounting to ¥44.15 billion.


Waiting for permission
Allow microphone access to enable voice search

Try again.